H MG-CoA reductase inhibitors (ie, statins) constitute a cornerstone in primary and secondary prevention of ischemic stroke.
H MG-CoA reductase inhibitors (ie, statins) constitute a cornerstone in primary and secondary prevention of ischemic stroke. 1 In addition to dose-dependent cholesterol-lowering effects, statins have dose-dependent pleiotropic effects, including antithrombotic properties, and were shown to modify fibrinolytic balance toward a more profibrinolytic state. 2 These properties may contribute to the beneficial impact of statins on outcome after ischemic stroke, which was recently confirmed in a large meta-analysis. 3 However, studies on patients receiving intravenous thrombolysis (IVT) reported conflicting results, and the effects on outcome seemed to be attenuated. [3] [4] [5] Rather, there has been a discussion that patients with previous statin use might be more likely to develop symptomatic intracerebral hemorrhage (sICH) after IVT. [5] [6] [7] A recently published meta-analysis showed a positive association of statins with IVT-related sICH, but the statistical significance was lost if only studies with adjusted analyses were included. 5 Previous studies investigating the impact of statins on outcome and sICH after IVT lacked information about statin dose. Using pooled data from 2 large European thrombolysis registries, we aimed to analyze the effects of statin dose on risk of sICH and outcome after IVT.
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Methods Study Population, Design, and Data Collection
All patients with acute ischemic stroke receiving IVT at the University Hospital Charité Berlin, Germany (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) , and University Hospital Basel, Switzerland (1998 Switzerland ( -2012 , were enrolled in prospective thrombolysis registries. Patients were being treated <3 hours after symptom onset until the European Cooperative Acute Stroke Study (ECASS) III was published in 2008. 8 Afterward, IVT was administered <4.5 hours. Previous data from the respective registries have been published before. 4, 9, 10 All patients were treated in a specialized stroke unit for ≥24 hours. The registries were approved by the respective ethics committees.
Baseline characteristics, including age, sex, and medical history (atrial fibrillation, coronary artery disease, current smoking, diabetes mellitus, hypertension, and previous stroke), were collected. Stroke severity was assessed via the National Institutes of Health Stroke Scale (NIHSS) by certified raters. Moreover, onsetto-treatment time and blood pressure on admission were recorded. Laboratory measures included glucose levels on admission, international normalized ratio on admission, as well as fasting low-density lipoprotein (LDL)-cholesterol levels. Information on previous use of antiplatelet drugs, anticoagulants, and statins (including type and dose) was collected.
Data were collected by physicians with experience in acute stroke care using predefined forms. 4 The NIHSS and modified Rankin Scale (mRS) were evaluated by certified raters. Both centers conducted a monthly check for completeness of data.
Definition of Statin Dose
Statin dose was categorized into 3 groups according to the attainable reduction of LDL-cholesterol described in head-to-head comparisons, because the potency of different statins to inhibit HMG-CoA reductase differs substantially. [11] [12] [13] At common therapeutic doses, the attainable reduction of LDL-cholesterol of available statins ranges between 25% and 55%. 11, 12 Statin doses with attainable lowering of LDL-cholesterol <35% were regarded low dose; attainable LDL lowering of 35% to 44% was defined medium dose; and attainable LDL lowering ≥45% was considered high dose (eg, a patient taking simvastatin 20 mg was considered low-dose statin user because of an attainable reduction of LDL-cholesterol <35% at this dose). The threshold of LDL lowering ≥45% for definition of high-potency statins has been applied before.
14,15 Table 1 shows the classification of statin dose according to the respective statin types.
Main Outcome Measures
Primary outcomes of our analysis were occurrence of sICH and favorable outcome at 3 months. sICH was defined as an ICH on followup cerebral imaging combined with clinical deterioration of ≥4 points on NIHSS, or death according to the criteria of the ECASS trial. 16 Moreover, radiological types of ICH were evaluated. Hemorrhagic infarction was differentiated from parenchymal hemorrhage type 1 and 2. 16 Functional outcome was assessed at 3 months (±7 days) using the mRS either by outpatient visit, telephone call, or postal questionnaire by a certified rater. 17 The mRS score was dichotomized into favorable (mRS 0-2) and unfavorable (mRS >2).
Statistical Methods
To identify differences between patients receiving different statin doses, the χ 2 test and Kruskal-Wallis test were used. Group comparisons of patients with and without sICH and favorable outcome were performed using the χ 2 test for categorical variables and the Wilcoxon-Mann-Whitney U-test for continuous variables.
Multivariable logistic regression analysis to calculate adjusted odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for the occurrence of sICH and favorable outcome was performed. Regarding favorable outcome, all variables significantly associated with outcome in univariate comparisons were considered for adjustment. Because of lower event rates, all variables associated with a P value <0.2 with sICH in univariate comparisons qualified for multivariable adjustment regarding sICH. In a sensitivity analysis, we added all variables associated with statin treatment to the regression model. Statin dose was entered into the models as a categorical variable (ie, low, medium, high). We also performed separate analyses using statin dose as continuous variable.
All tests were 2-tailed, and statistical significance was determined at α level of 0.05. Statistical analyses were performed using SPSS, version 19.0, for Windows.
Results
Among 1455 patients, 1446 (99.4%) were eligible for analysis. Patients were excluded for missing data about statin use or dose (n=6) or lacking information about sICH (n=3). The Berlin cohort consisted of 781 patients (median age, 75; median NIHSS score, 10; previous statin use, 22 .4%; sICH rate, 3.9%; favorable outcome, 46.8%) and the Basel cohort consisted of 660 patients (median age, 74; median NIHSS score, 12; previous statin use, 21.4%; sICH rate, 3.3%; favorable outcome, 58.9%). Overall, the median age of the study population was 75 years, and the median NIHSS score was 11. Previous statin use (any dose) was identified in 317 patients (22%), including 120 patients with low-dose, 134 with medium-dose, and 63 with high-dose therapy. Statins used in our cohort were simvastatin (n=183; 12.7%), atorvastatin (n=84; 5.8%), pravastatin (n=36; 2.5%), fluvastatin (n=9; 0.6%), and rosuvastatin (n=5; 0.3%). Baseline characteristics of patients receiving different statin doses are depicted in Table 2 . In total, sICH occurred in 53 patients (3.7%). In univariate comparisons, patients with sICH were more severely affected by the stroke, had significantly higher blood pressure on admission, and were more likely to use antiplatelets and statins before IVT (Table 3) . Occurrence of sICH differed significantly in patients receiving different statin doses before IVT (P<0.01; P for trend, <0.01). Frequency of sICH in patients with previous low-, medium-, and high-dose statin use was 1.7%, 6.0%, and 12.7%, respectively. The increase of sICH was observed separately in both cohorts (P for trend, <0.01 for each cohort). The dose-related association of previous statin use with sICH held true after adjusting for age, initial stroke severity (NIHSS), blood glucose levels, blood pressure on admission, current smoking, and concomitant use of antiplatelet drugs in a multivariable regression analysis (P<0.01; Table 3 ). Patients with medium-and high-dose statin use had ≈2.5-fold and 5-fold higher OR, respectively, for sICH compared with non-statin users. In addition, higher stroke severity (P=0.02) and higher blood pressure (P<0.01) were independently associated with sICH. Similar results were detected regarding occurrence of parenchymal hemorrhage. Statin dose was independently associated with parenchymal hemorrhage after adjustment for the abovementioned variables (P<0.01). More details regarding the analyses of different radiological subtypes of ICH are shown in Table I in the online-only Data Supplement.
We conducted a further regression analysis with additional inclusion of LDL-cholesterol levels and all other variables significantly associated with previous statin use (male sex, onset-to-treatment time, diabetes mellitus, hypertension, coronary artery disease, and previous stroke). The independent association of statin dose remained (P=0.03), whereas no effect of LDL-cholesterol levels (P=0.18) on the occurrence of sICH was detected (Table 3) . We performed additional analyses on the association of certain statin types with sICH. A dose-related increase of sICH was observed in patients treated with simvastatin as well as atorvastatin (both P for trend, 0.01; Table II 
Discussion
The findings of our study indicate a dose-related effect of statins on sICH after IVT. The risk of sICH increased with higher statin doses. Despite the increased risk of sICH, patients with previous statin use had better functional outcomes compared with non-statin users. The association was similar across all doses, although it was attenuated and not significant in the high-dose group. Both findings might be attributed to the pleiotropic effects of statins on profibrinolytic and antithrombotic pathways. 2, 18 Similar to the cholesterol-lowering properties of statins, most pleiotropic properties have been shown to be mediated by HMG-CoA reductase inhibition and are dose-dependent. 2, 18 In a rat model of embolic stroke, statin-treated animals showed smaller residual clot size and smaller infarct volumes, indicating that statins may promote recanalization. 19 Also, in stroke patients undergoing endovascular procedures, statins were linked to better recanalization, 20 although this was not confirmed in a larger study. 5 Furthermore, pre-existing statin treatment has been associated with greater reperfusion after acute stroke. 21 Overall, this may increase the risk of sICH, but may also result in improved clinical outcome. Interestingly, a recent study showed an association of pretreatment with statins and mild stroke severity on admission, which was pronounced in patients with high-dose statin therapy. 22 A part of the observed effects in our study might be explained by lower cholesterol levels in statin users. Lower cholesterol has been identified as a risk factor for ICH and has been linked to hemorrhagic transformation in the setting of thrombolysis. 23, 24 In our study, cholesterol levels were not different in patients with and without sICH and not significantly associated with sICH in a multivariable regression analysis. This is in line with recently published data from a multicenter study comprising >1800 patients, which did not find an association of lower cholesterol levels with sICH or outcome. 25 Several previous studies reported a positive, but not significant, association of statins with sICH after IVT. 7 For instance, pooled data from 11 European stroke centers and a recent meta-analysis indicated an increased risk of sICH in patients with previous statin use, which closely failed to reach statistical significance after multivariable adjustment. 4, 5 It has been discussed that baseline characteristics of statin users might indicate an unfavorable prestroke morbidity, leading to a higher chance of developing sICH after IVT. 4 As shown in our study, these unfavorable characteristics seem to accumulate in high-dose statin users. This may, at least in part, account for the higher risk of sICH in this subgroup.
Despite the increased risk of sICH, statin users more often had a favorable 3-month outcome compared with nonusers. The association with favorable outcome remained significant after adjustment for possible confounders. It was similar across all dose groups, although it was not significant in the high-dose group anymore. Our findings are in line with the growing body of evidence linking statins to improved stroke outcomes. 3, 26 However, in stroke patients receiving IVT, the beneficial effects have not been observed consistently. Alvarez-Sabin et al 27 detected better outcomes after IVT in patients with pre-existing statin use. In addition, a recent multicenter study indicated improved outcomes in stroke patients with statin use in the acute phase after IVT. 28 However, this was not confirmed by others. 3, 4, 29 The reason why our findings were not observed in all previous studies could be the differences regarding statin dose and the smaller sample size of previous studies.
Our study has several limitations. First, because of the retrospective design, we do not have information about recanalization status for the entire cohort. Therefore, it remains hypothetical whether our observations are related to improvement of recanalization or reperfusion triggered by statins. Second, the dose classification applied in our study was based on comparative efficacy of different statins on LDLcholesterol lowering. However, we cannot provide data on pre-statin therapy lipid profile, duration of statin therapy, and compliance of the patients. Therefore, the extent of cholesterol lowering in the individual patient in our cohort might differ from the theoretically attainable cholesterol lowering reported in meta-analyses of clinical trials. Third, we do not have information whether statin dose was continued during hospital stay and after hospital discharge. It was shown that discontinuation of statins or reduction in statin dose during hospitalization and after hospital discharge has been associated with unfavorable outcome and mortality. 7, 30 Fourth, we did not collect information about imaging predictors of sICH, such as severity of leukoaraiosis and stroke lesion volume. 31 Fifth, despite multiple adjustments, additional but unrecorded covariates might have influenced our findings. Therefore and because of the observational design, our results should be interpreted cautiously.
In conclusion, our findings indicate a dose-related effect of statins on risk of sICH after IVT. Nevertheless, previous statin use was independently associated with favorable 3-month outcome, although this effect was less convincing in the highdose group.
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